NASDAQ: NAGENiagen Bioscience Inc Stock
$14.41+0.19 (+1.34%)
Updated Jun 30, 2025
NAGE Price
$14.41
Fair Value Price
-$1.41
Market Cap
$1.14B
52 Week Low
$2.41
52 Week High
$14.69
P/E
80.06x
P/B
20.51x
P/S
4.98x
PEG
11.09x
Dividend Yield
N/A
Revenue
$107.93M
Earnings
$14.11M
Gross Margin
62.5%
Operating Margin
13.51%
Profit Margin
13.1%
Debt to Equity
0.47
Operating Cash Flow
$20M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NAGE Overview
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NAGE's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important NAGE news, forecast changes, insider trades & much more!
NAGE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAGE ($14.41) is overvalued by 1,122.35% relative to our estimate of its Fair Value price of -$1.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NAGE ($14.41) is not significantly undervalued (1,122.35%) relative to our estimate of its Fair Value price of -$1.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NAGE ($14.41) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NAGE due diligence checks available for Premium users.
Valuation
NAGE fair value
Fair Value of NAGE stock based on Discounted Cash Flow (DCF)
Price
$14.41
Fair Value
-$1.41
Undervalued by
1,122.35%
NAGE ($14.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NAGE ($14.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NAGE ($14.41) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
80.06x
Industry
-123.86x
Market
32.47x
NAGE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NAGE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
NAGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.51x
Industry
4.44x
NAGE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAGE price to earnings growth (PEG)
For valuing profitable companies with growth potential
NAGE is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
NAGE's financial health
Profit margin
Revenue
$30.5M
Net Income
$5.1M
Profit Margin
16.6%
NAGE's Earnings (EBIT) of $14.58M... subscribe to Premium to read more.
Interest Coverage Financials
NAGE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$81.3M
Liabilities
$26.0M
Debt to equity
0.47
NAGE's short-term assets ($76.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAGE's short-term assets ($76.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.9M
Investing
-$32.0k
Financing
$3.1M
NAGE's operating cash flow ($19.70M)... subscribe to Premium to read more.
Debt Coverage Financials
NAGE vs Biotech Stocks
Niagen Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.